NEGGRAM
LOE ApproachingNDAORALTABLETPriority Review
Approved
Mar 1964
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 7h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEGGRAM is an oral small-molecule tablet approved in 1964 by Sanofi under NDA. The generic name and mechanism of action are not currently available in this dataset. Patient population and therapeutic indication cannot be determined from available data.
LOE Approaching
With LOE approaching and competitive pressure at 30%, the brand team is likely in transition mode, focusing on exclusivity defense or preparing for generic erosion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job opportunities indicate minimal active hiring for NEGGRAM roles. Working on this product offers limited growth trajectory but stable legacy franchise experience. Pharma professionals should expect downsizing activity and transition planning rather than career expansion.
Brand ManagerField Sales Representative
Worked on NEGGRAM at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.